MedTrace Logo

IV Lidocaine Infusion for Neuropathic Pain

NCT05731739 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-02-16

No results posted yet for this study

Summary

The investigators will conduct a retrospective cohort study of patients who have undergone i.v. lidocaine infusions in the previous 2 years for suspected neuropathic pain of heterogeneous origin. The investigators hypothesize that the analgesic response to intravenous (i.v.) lidocaine will be bimodal with clear responders and clear non-responders. The investigators also hypothesize that more refractory patients, who have failed previous multimodal analgesic therapy, will be less likely to respond to i.v. lidocaine. The investigators goals are to report what percentage of patients will achieve relief, the degree of relief that can be expected, and identify the type of patients who will most likely to benefit from systemic lidocaine. The investigators secondary objective is to report the correlation between infusion rates and patterns of infusion rate adjustments with regard to efficacy and adverse effects.

Conditions

  • Neuropathic Pain
  • Complex Regional Pain Syndrome
  • Chronic Pain

Sponsors & Collaborators

  • Henry Ford Health System

    lead OTHER

Principal Investigators

  • NABIL SIBAI, M.D. · HENRY FORD HEALTH SYSTEMS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2023-01-31
Completion
2023-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05731739 on ClinicalTrials.gov